The research on the novel F-18 radiolabeled poly (ADP-ribose) polymerase (PARP) inhibitor THG-008 is expected to begin in February 2021. Evidence has already shown that the agent can be used for imaging head and neck cancer. It can detect primary and metastatic head and neck squamous cell carcinoma lesions, and retention in cancer deposits was longer than in healthy tissues.